Biofrontera Inc Financials
Biofrontera Inc (BFRI) reported $41.7M in revenue for fiscal year 2025, up 11.7% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Biofrontera's commercial scale-up is narrowing losses, but cash burn still leaves the business dependent on outside funding.
Across FY2023-FY2025, revenue growth and a much narrower operating loss suggest the business is finally getting some operating leverage from its commercial footprint rather than simply spending more to chase sales. But FY2025 operating cash flow was-$13.4M against only$6.4M of cash, so the improvement in reported results has not yet translated into a self-funded business.
The margin improvement looks more like fixed-cost absorption than deep retrenchment. SG&A was still
The liquidity picture is increasingly about working-capital mix, not just headline current assets. Inventory fell to
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Biofrontera Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Biofrontera Inc scores -5.12, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($22.4M) relative to total liabilities ($18.1M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Biofrontera Inc passes 1 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.
Biofrontera Inc reported a net loss of $10.5M while operations used $13.4M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Biofrontera Inc generated $41.7M in revenue in fiscal year 2025. This represents an increase of 11.7% from the prior year.
Biofrontera Inc's EBITDA was -$11.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 33.2% from the prior year.
Biofrontera Inc reported -$10.5M in net income in fiscal year 2025. This represents an increase of 40.7% from the prior year.
Cash & Balance Sheet
Biofrontera Inc recorded an outflow of $13.4M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents a decrease of 30.0% from the prior year.
Biofrontera Inc held $6.4M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Margins & Returns
Biofrontera Inc's operating margin was -27.2% in fiscal year 2025, reflecting core business profitability. This is up 18.9 percentage points from the prior year.
Biofrontera Inc's net profit margin was -25.3% in fiscal year 2025, showing the share of revenue converted to profit. This is up 22.3 percentage points from the prior year.
Biofrontera Inc's ROE was -100.5% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 300.1 percentage points from the prior year.
Not reported for fiscal year 2025.
Capital Allocation
Biofrontera Inc invested $3.7M in research and development in fiscal year 2025. This represents an increase of 78.0% from the prior year.
Biofrontera Inc invested $2K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 80.0% from the prior year.
Not reported for fiscal year 2025.
BFRI Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 |
|---|---|---|---|---|---|---|---|
| Revenue | $46.2M | $41.7M+11.7% | $37.3M+9.5% | $34.1M+18.8% | $28.7M+19.0% | $24.1M+27.9% | $18.8M |
| R&D Expenses | $3.0M | $3.7M+78.0% | $2.1M+2613.0% | $77K | N/A | N/A | N/A |
| SG&A Expenses | $39.2M | $37.8M+11.7% | $33.8M-13.3% | $39.0M+10.9% | $35.1M-3.8% | $36.5M+106.2% | $17.7M |
| Operating Income | -$6.6M | -$11.3M+34.1% | -$17.2M+24.1% | -$22.7M-22.0% | -$18.6M+26.3% | -$25.2M-162.3% | -$9.6M |
| Interest Expense | N/A | N/A | N/A | $220K+1733.3% | $12K-96.5% | $344K-88.0% | $2.9M |
| Income Tax | N/A | $25K+13.6% | $22K+57.1% | $14K-56.3% | $32K-42.9% | $56K-12.5% | $64K |
| Net Income | -$6.4M | -$10.5M+40.7% | -$17.8M+11.8% | -$20.1M-3045.5% | -$640K+98.3% | -$37.7M-243.3% | -$11.0M |
| EPS (Diluted) | — | -$1.04 | -$3.22 | -$13.02-2034.4% | -$0.61 | N/A | N/A |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
BFRI Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 |
|---|---|---|---|---|---|---|
| Total Assets | $28.6M+29.2% | $22.1M-20.9% | $27.9M-45.1% | $50.9M-4.4% | $53.2M+120.5% | $24.1M |
| Current Assets | $18.1M-12.6% | $20.7M-10.3% | $23.1M-46.5% | $43.1M-7.1% | $46.4M+137.1% | $19.6M |
| Cash & Equivalents | $6.4M+8.2% | $5.9M+339.7% | $1.3M-92.2% | $17.2M-29.9% | $24.5M+203.8% | $8.1M |
| Inventory | $1.4M-78.5% | $6.6M-39.1% | $10.9M+52.2% | $7.2M+60.8% | $4.5M-37.1% | $7.1M |
| Accounts Receivable | $7.3M+37.2% | $5.3M+3.0% | $5.2M+37.7% | $3.7M-1.0% | $3.8M+17.7% | $3.2M |
| Total Liabilities | $18.1M+2.4% | $17.7M-23.6% | $23.1M-14.3% | $27.0M-35.5% | $41.9M+128.7% | $18.3M |
| Current Liabilities | $11.9M-1.0% | $12.0M-33.5% | $18.1M-13.4% | $20.9M+51.0% | $13.8M+213.0% | $4.4M |
| Total Equity | $10.5M+136.4% | $4.4M-7.5% | $4.8M-79.9% | $23.9M+110.6% | $11.3M+94.5% | $5.8M |
| Retained Earnings | -$127.9M-9.0% | -$117.4M-17.8% | -$99.7M-25.3% | -$79.5M-0.8% | -$78.9M-91.6% | -$41.2M |
Not reported in any period shown, so not listed: Goodwill, Long-Term Debt.
BFRI Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$7.9M | -$13.4M-30.1% | -$10.3M+58.7% | -$24.9M-53.7% | -$16.2M+39.4% | -$26.7M-116.0% | -$12.4M |
| Capital Expenditures | $3K | $2K-80.0% | $10K+100.0% | $5K-86.8% | $38K | N/A | N/A |
| Free Cash Flow | -$7.9M | -$13.4M-30.0% | -$10.3M+58.7% | -$24.9M-53.4% | -$16.2M | N/A | N/A |
| Investing Cash Flow | $3.0M | $3.0M+100033.3% | -$3K-100.5% | $619K+112.0% | -$5.2M-46772.7% | -$11K | N/A |
| Financing Cash Flow | N/A | $10.8M-26.9% | $14.8M+76.4% | $8.4M-40.0% | $14.0M-67.5% | $43.2M+227.4% | $13.2M |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
BFRI Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 |
|---|---|---|---|---|---|---|
| Operating Margin | -27.2%+18.9pp | -46.1%+20.4pp | -66.6%-1.8pp | -64.8% | -104.6% | -51.0% |
| Net Margin | -25.3%+22.3pp | -47.6%+11.5pp | -59.1%-56.9pp | -2.2% | -156.5% | -58.3% |
| Return on Equity | -100.5%+300.1pp | -400.6%+19.4pp | -420.0%-417.3pp | -2.7%+329.9pp | -332.6%-144.1pp | -188.5% |
| Return on Assets | -36.9%+43.5pp | -80.3%-8.3pp | -72.1%-70.8pp | -1.3%+69.6pp | -70.9%-25.3pp | -45.5% |
| Current Ratio | 1.52-0.2x | 1.72+0.4x | 1.28-0.8x | 2.06-1.3x | 3.36-1.1x | 4.43 |
| Debt-to-Equity | 1.73-2.3x | 3.99-0.8x | 4.83+3.7x | 1.13-2.6x | 3.69+0.6x | 3.14 |
| FCF Margin | -32.0%-4.5pp | -27.5%+45.5pp | -73.1%-16.4pp | -56.6% | N/A | N/A |
Not reported in any period shown, so not listed: Gross Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin.
Similar Companies
Where Biofrontera Inc Ranks
Frequently Asked Questions
What is Biofrontera Inc's annual revenue?
Biofrontera Inc (BFRI) reported $41.7M in total revenue for fiscal year 2025. This represents a 11.7% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Biofrontera Inc's revenue growing?
Biofrontera Inc (BFRI) revenue grew by 11.7% year-over-year, from $37.3M to $41.7M in fiscal year 2025.
Is Biofrontera Inc profitable?
No, Biofrontera Inc (BFRI) reported a net income of -$10.5M in fiscal year 2025, with a net profit margin of -25.3%.
What is Biofrontera Inc's EBITDA?
Biofrontera Inc (BFRI) had EBITDA of -$11.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Biofrontera Inc's operating margin?
Biofrontera Inc (BFRI) had an operating margin of -27.2% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Biofrontera Inc's net profit margin?
Biofrontera Inc (BFRI) had a net profit margin of -25.3% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Biofrontera Inc's return on equity (ROE)?
Biofrontera Inc (BFRI) has a return on equity of -100.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Biofrontera Inc's free cash flow?
Biofrontera Inc (BFRI) recorded an outflow of $13.4M in free cash flow during fiscal year 2025. This represents a -30.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Biofrontera Inc's operating cash flow?
Biofrontera Inc (BFRI) recorded an outflow of $13.4M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Biofrontera Inc's total assets?
Biofrontera Inc (BFRI) had $28.6M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Biofrontera Inc's capital expenditures?
Biofrontera Inc (BFRI) invested $2K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Biofrontera Inc spend on research and development?
Biofrontera Inc (BFRI) invested $3.7M in research and development during fiscal year 2025.
What is Biofrontera Inc's current ratio?
Biofrontera Inc (BFRI) had a current ratio of 1.52 as of fiscal year 2025, which is generally considered healthy.
What is Biofrontera Inc's debt-to-equity ratio?
Biofrontera Inc (BFRI) had a debt-to-equity ratio of 1.73 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Biofrontera Inc's return on assets (ROA)?
Biofrontera Inc (BFRI) had a return on assets of -36.9% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Biofrontera Inc's Altman Z-Score?
Biofrontera Inc (BFRI) has an Altman Z-Score of -5.12, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Biofrontera Inc's Piotroski F-Score?
Biofrontera Inc (BFRI) has a Piotroski F-Score of 1 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Biofrontera Inc's earnings high quality?
Biofrontera Inc (BFRI) reported a net loss of $10.5M while operations used $13.4M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Biofrontera Inc?
Biofrontera Inc (BFRI) scores 41 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.